» Articles » PMID: 6980881

Proteolytic Cleavage and Inactivation of Alpha 2-plasmin Inhibitor and C1 Inactivator by Human Polymorphonuclear Leukocyte Elastase

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1982 Aug 25
PMID 6980881
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

This study has examined the interaction between human leukocyte elastase and alpha 2-plasmin inhibitor, or C1 inactivator, inhibitors of proteases of the complement, kinin, coagulation, and fibrinolytic enzyme systems. Leukocyte elastase, in catalytic concentrations, progressively inactivates the plasmin inhibitory activity of both inhibitors. The C1s binding function of C1 inactivator is also destroyed by leukocyte elastase. The nature of the molecular events underlying the inactivation of these protease inhibitors was examined by acrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. Loss of functional activity was accompanied by limited proteolytic cleavage of both inhibitors with the production of several characteristic derivative peptide chains. Leukocyte elastase cleaved alpha 2-plasmin inhibitor at two separate sites and generated lower molecular weight fragments similar to those produced by bovine beta-trypsin. C1 inactivator was hydrolyzed at three different regions on the molecule whereas beta-trypsin cleaved two regions in common with leukocyte elastase. These findings suggest that inactivation of alpha 2-plasmin inhibitor and C1 inactivator by leukocyte elastase released in the inflammatory reaction may potentiate pathological proteolysis. The limited digestion of these inhibitory proteins by leukocyte elastase may prove useful in studies of their primary structure.

Citing Articles

Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.

Zheng Z, Mukhametova L, Boffa M, Moore E, Wolberg A, Urano T J Thromb Haemost. 2023; 21(4):1043-1054.

PMID: 36759279 PMC: 10109242. DOI: 10.1016/j.jtha.2023.01.008.


Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.

Alsayejh B, Kietsiriroje N, Almutairi M, Simmons K, Pechlivani N, Ponnambalam S TH Open. 2022; 6(4):e396-e407.

PMID: 36452200 PMC: 9674435. DOI: 10.1055/a-1957-6817.


Roles of Immune Cells in Hereditary Angioedema.

Ferrara A, Cristinziano L, Petraroli A, Bova M, Gigliotti M, Marcella S Clin Rev Allergy Immunol. 2021; 60(3):369-382.

PMID: 34050913 PMC: 8272703. DOI: 10.1007/s12016-021-08842-9.


ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism.

Pihl R, Jensen R, Poulsen E, Jensen L, Hansen A, Thogersen I Sci Adv. 2021; 7(2).

PMID: 33523981 PMC: 7793589. DOI: 10.1126/sciadv.aba7381.


Joint Measurements of Leukocyte Elastase and Myeloperoxidase Promote Identification of the State of Neutrophils in Diabetic Patients.

Alexandrovski M, Suciu S, Alexandrovski J Biores Open Access. 2020; 9(1):190-197.

PMID: 32908806 PMC: 7473041. DOI: 10.1089/biores.2020.0012.